The U.S. Court of Appeals for the Federal Circuit issued two significant decisions last year that affect the protection of biotechnology through the use of functional genus claims — Amgen Inc. v. Sanofi and Juno Therapeutics Inc. v. Kite Pharma Inc.
Please see full publication below for more information.
LOADING PDF: If there are any problems, click here to download the file.
